Psychometric evaluation of ADAS‐Cog and NTB for measuring drug response. (13th June 2013)
- Record Type:
- Journal Article
- Title:
- Psychometric evaluation of ADAS‐Cog and NTB for measuring drug response. (13th June 2013)
- Main Title:
- Psychometric evaluation of ADAS‐Cog and NTB for measuring drug response
- Authors:
- Karin, A.
Hannesdottir, K.
Jaeger, J.
Annas, P.
Segerdahl, M.
Karlsson, P.
Sjögren, N.
von, T.
Miller, F. - Abstract:
- <abstract abstract-type="main" id="ane12153-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ane12153-sec-0001" sec-type="section"> <title>Aims</title> <p>To conduct a psychometric analysis to determine the adequacy of instruments that measure cognition in Alzheimer's disease trials.</p> </sec> <sec id="ane12153-sec-0002" sec-type="section"> <title>Background</title> <p>Both the Alzheimer's Disease Assessment Scale ‐ Cognition (ADAS‐Cog) and the Neuropsychological Test Battery (NTB) are validated outcome measures for clinical trials in Alzheimer's disease and are approved also for regulatory purposes. However, it is not clear how comparable they are in measuring cognitive function. In fact, many recent trials in Alzheimer's disease patients have failed and it has been questioned if ADAS‐Cog still is a sensitive measure.</p> </sec> <sec id="ane12153-sec-0003" sec-type="section"> <title>Materials and Methods</title> <p>The present paper examines the psychometric properties of ADAS‐Cog and NTB, based on a post hoc analysis of data from a clinical trial (NCT01024660), which was conducted by AstraZeneca, in mild‐to‐moderate Alzheimer's disease (AD) patients, with a Mini Mental State Examination (MMSE) Total score 16‐24. Acceptability, reliability, different types of validity and ability to detect change were assessed using relevant statistical methods. Total scores of both tests, as well as separate domains of both tests, including the Wechsler Memory<abstract abstract-type="main" id="ane12153-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ane12153-sec-0001" sec-type="section"> <title>Aims</title> <p>To conduct a psychometric analysis to determine the adequacy of instruments that measure cognition in Alzheimer's disease trials.</p> </sec> <sec id="ane12153-sec-0002" sec-type="section"> <title>Background</title> <p>Both the Alzheimer's Disease Assessment Scale ‐ Cognition (ADAS‐Cog) and the Neuropsychological Test Battery (NTB) are validated outcome measures for clinical trials in Alzheimer's disease and are approved also for regulatory purposes. However, it is not clear how comparable they are in measuring cognitive function. In fact, many recent trials in Alzheimer's disease patients have failed and it has been questioned if ADAS‐Cog still is a sensitive measure.</p> </sec> <sec id="ane12153-sec-0003" sec-type="section"> <title>Materials and Methods</title> <p>The present paper examines the psychometric properties of ADAS‐Cog and NTB, based on a post hoc analysis of data from a clinical trial (NCT01024660), which was conducted by AstraZeneca, in mild‐to‐moderate Alzheimer's disease (AD) patients, with a Mini Mental State Examination (MMSE) Total score 16‐24. Acceptability, reliability, different types of validity and ability to detect change were assessed using relevant statistical methods. Total scores of both tests, as well as separate domains of both tests, including the Wechsler Memory Scale (WMS), Rey Auditory Verbal Learning Test (RAVLT) and Delis‐Kaplan Executive Function System (D‐KEFS) Verbal Fluency Condition, were analyzed.</p> </sec> <sec id="ane12153-sec-0004" sec-type="section"> <title>Results</title> <p>Overall, NTB performed well, with acceptable reliability and ability to detect change, while ADAS‐Cog had insufficient psychometric properties, including ceiling effects in 8 out of a total of 11 ADAS‐Cog items in mild AD patients, as well as low test‐retest reliability in some of the items.</p> </sec> <sec id="ane12153-sec-0005" sec-type="section"> <title>Discussion</title> <p>Based on a direct comparison on the same patient sample, we see advantages of the NTB compared with the ADAS‐Cog for the evaluation of cognitive function in the population of mild‐to‐moderate AD patients. The results suggest that not all of ADAS‐Cog items are relevant for both mild and moderate AD population.</p> </sec> <sec id="ane12153-sec-0006" sec-type="section"> <title>Conclusions</title> <p>This validation study demonstrates satisfactory psychometric properties of the NTB, while ADAS‐Cog was found to be psychometrically inadequate.</p> </sec> </abstract> … (more)
- Is Part Of:
- Acta neurologica Scandinavica. Volume 129:Number 2(2014:Feb.)
- Journal:
- Acta neurologica Scandinavica
- Issue:
- Volume 129:Number 2(2014:Feb.)
- Issue Display:
- Volume 129, Issue 2 (2014)
- Year:
- 2014
- Volume:
- 129
- Issue:
- 2
- Issue Sort Value:
- 2014-0129-0002-0000
- Page Start:
- 114
- Page End:
- 122
- Publication Date:
- 2013-06-13
- Subjects:
- Neurology -- Periodicals
616.8 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1111/ane.12153 ↗
- Languages:
- English
- ISSNs:
- 0001-6314
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0639.910000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3641.xml